Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...
13d
Hosted on MSNMRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority TagMerck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral ...
14d
Hosted on MSNMSD wins FDA priority review for Welireg in rare endocrine cancerThe US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The treatment for Simon Goodrich’s disease has been costing $12,000 a month, but there has been a huge development.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results